<DOC>
	<DOCNO>NCT00950430</DOCNO>
	<brief_summary>This prospective , open label , non-therapeutic , diagnostic imaging study . The purpose study utilize Pittsburgh Compound B positron emission imaging ( PiB PET ) ascertain relationship change amyloid burden time , concurrent change clinical status .</brief_summary>
	<brief_title>Imaging Brain Amyloid Plaques Aging Population</brief_title>
	<detailed_description>Identification risk factor biomarkers neurodegenerative disease essential care grow number elderly . Imaging biomarkers provide non-invasive way look brain function . A new PET imaging agent , Pittsburgh Compound B ( PiB ) , identifies brain amyloid excite development brain imaging need study . We plan study imaging technique normal volunteer patient variety neurodegenerative disease determine utility . Long term followup subject allow u understand predictive ability new test .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Dementia , Vascular</mesh_term>
	<mesh_term>Frontotemporal Dementia</mesh_term>
	<mesh_term>Aphasia , Primary Progressive</mesh_term>
	<mesh_term>Pick Disease Brain</mesh_term>
	<mesh_term>Lewy Body Disease</mesh_term>
	<mesh_term>Corticosterone</mesh_term>
	<criteria>Age 30100 Subjects complete schedule undergo neurological evaluation procedure Mayo Clinic Study Aging , Mayo ADRC , Mayo neurodegenerative disease clinic . Subjects unable lie without move 10 minute Women pregnant stop breast feed 24 hour Claustrophobic patient unable tolerate scan Standard safety exclusionary criterion MRI metallic foreign body , pacemaker , etc .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Imaging</keyword>
	<keyword>PET</keyword>
	<keyword>PiB</keyword>
	<keyword>FDG</keyword>
	<keyword>MCI</keyword>
	<keyword>Dementia</keyword>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Brain Amyloid</keyword>
</DOC>